OncoSil Medical Ltd. (ASX:OSL), a company dedicated to advancing cancer treatment through innovative localised therapies, is pushing forward with two pivotal clinical trials: TRIPP-FFX and PANCOSIL. These trials are critical to their strategy of expanding the applications and accessibility of their flagship device, OncoSil™. This device delivers localised radiation therapy directly to pancreatic tumours, potentially improving treatment outcomes for patients with locally advanced unresectable pancreatic cancer (LAPC).
The TRIPP-FFX Clinical Study
The TRIPP-FFX trial is a crucial component of OncoSil’s mission to refine and enhance their therapeutic options for pancreatic cancer. This open-label, multi-centre, randomised study is investigating the use of OncoSil™ in conjunction with FOLFIRINOX chemotherapy, a regimen known for its effectiveness in treating LAPC. Unlike previous research that focused on combining OncoSil™ with gemcitabine-based chemotherapy, TRIPP-FFX is exploring its use with FOLFIRINOX, aiming to broaden the treatment options for patients with unresectable pancreatic cancer.
The primary goals of the TRIPP-FFX trial are to assess the safety, tolerability, and local disease control rate at 16 weeks when OncoSil™ is used alongside FOLFIRINOX. Secondary objectives include evaluating overall survival, quality of life, pain management, tumour response, and surgical resection rates. These comprehensive endpoints will help determine whether integrating OncoSil™ with FOLFIRINOX can provide a more robust therapeutic protocol for pancreatic cancer.
The success of this trial could significantly increase the eligible patient population for OncoSil™. By combining these chemotherapeutic agents, OncoSil hopes to provide patients with a more comprehensive treatment option that may help them achieve better results than they might with just current therapies. The expanded protocol could provide a much-needed alternative for those with advanced or hard-to-treat pancreatic cancers, positioning OncoSil™ as a cornerstone in multimodal cancer therapy.
PANCOSIL Clinical Trial
Simultaneously, the PANCOSIL trial is exploring a novel approach to administering OncoSil™ through CT-guided percutaneous delivery. This Investigator Initiated Clinical Trial is designed to evaluate the safety and feasibility of using OncoSil™ in patients with non-progressive LAPC. Unlike traditional surgical methods, percutaneous application is minimally invasive and allows for precise delivery of the radioactive device directly into the tumour.
The PANCOSIL trial, which will treat 20 patients, aims to expand the use of OncoSil™ by enabling interventional radiologists to deliver the device. This method could significantly enhance the flexibility and accessibility of OncoSil™ treatment, especially in healthcare systems where interventional radiology plays a prominent role. The trial's focus on safety and feasibility will provide valuable insights into the potential of this delivery method to complement existing surgical and chemotherapy options.
By demonstrating the efficacy and safety of administering OncoSil™ through interventional radiology, the PANCOSIL trial could open new avenues for the treatment's adoption across different medical practices and regions. It could also facilitate quicker and wider acceptance among healthcare providers, enhancing OncoSil's market penetration and ultimately benefiting a larger patient population.
How is OncoSil Medical Broadening Market Reach and Adoption?
For OncoSil, the TRIPP-FFX and PANCOSIL trials are not just research endeavours but strategic initiatives designed to expand their market presence and product applicability. By exploring the combination of OncoSil™ with FOLFIRINOX and pioneering new delivery methods through percutaneous application, OncoSil aims to position their device as a cornerstone in the treatment of LAPC.
These trials underscore OncoSil’s commitment to improving cancer treatment outcomes and broadening their global footprint. By aligning their product with diverse healthcare systems and patient needs, OncoSil is poised to enhance its market penetration and provide more effective and adaptable cancer therapies.
OncoSil Medical’s focused approach to conducting the TRIPP-FFX and PANCOSIL trials highlights their dedication to advancing cancer treatment through innovative solutions. By combining OncoSil™ with established chemotherapy agents and exploring new delivery methods, these trials aim to expand the therapeutic uses of OncoSil™ and integrate it into a broad spectrum of cancer treatment protocols. As these trials progress, OncoSil is well-positioned to make a significant impact on the field of oncology, ultimately improving patient outcomes and solidifying its place in the global market.
